WO2017199008A1 - Émulsion - Google Patents
Émulsion Download PDFInfo
- Publication number
- WO2017199008A1 WO2017199008A1 PCT/GB2017/051343 GB2017051343W WO2017199008A1 WO 2017199008 A1 WO2017199008 A1 WO 2017199008A1 GB 2017051343 W GB2017051343 W GB 2017051343W WO 2017199008 A1 WO2017199008 A1 WO 2017199008A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- active ingredients
- hydrocolloid
- typically
- solution
- Prior art date
Links
- 239000000839 emulsion Substances 0.000 title claims abstract description 64
- 239000000203 mixture Substances 0.000 claims abstract description 56
- 239000004480 active ingredient Substances 0.000 claims abstract description 53
- 239000000416 hydrocolloid Substances 0.000 claims abstract description 53
- 238000000034 method Methods 0.000 claims abstract description 43
- 230000008569 process Effects 0.000 claims abstract description 34
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 33
- 239000000243 solution Substances 0.000 claims abstract description 33
- 239000002245 particle Substances 0.000 claims abstract description 29
- 239000007864 aqueous solution Substances 0.000 claims abstract description 28
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 19
- 238000010008 shearing Methods 0.000 claims abstract description 18
- 239000003125 aqueous solvent Substances 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims description 19
- -1 antibodies Proteins 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 15
- 229940124597 therapeutic agent Drugs 0.000 claims description 15
- 235000010418 carrageenan Nutrition 0.000 claims description 7
- 229920001525 carrageenan Polymers 0.000 claims description 7
- 239000000679 carrageenan Substances 0.000 claims description 7
- 229940113118 carrageenan Drugs 0.000 claims description 7
- 229920002678 cellulose Polymers 0.000 claims description 7
- 239000001913 cellulose Substances 0.000 claims description 7
- 235000010980 cellulose Nutrition 0.000 claims description 7
- 239000002736 nonionic surfactant Substances 0.000 claims description 7
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 7
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 6
- 229940072056 alginate Drugs 0.000 claims description 6
- 235000010443 alginic acid Nutrition 0.000 claims description 6
- 229920000615 alginic acid Polymers 0.000 claims description 6
- 239000003945 anionic surfactant Substances 0.000 claims description 6
- 239000003093 cationic surfactant Substances 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 238000002844 melting Methods 0.000 claims description 6
- 230000008018 melting Effects 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 235000015097 nutrients Nutrition 0.000 claims description 5
- 229920001817 Agar Polymers 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- 239000008272 agar Substances 0.000 claims description 4
- 235000010419 agar Nutrition 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 229920001277 pectin Polymers 0.000 claims description 4
- 235000010987 pectin Nutrition 0.000 claims description 4
- 239000001814 pectin Substances 0.000 claims description 4
- 229960000292 pectin Drugs 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 3
- 244000215068 Acacia senegal Species 0.000 claims description 3
- 229920000936 Agarose Polymers 0.000 claims description 3
- 239000001879 Curdlan Substances 0.000 claims description 3
- 229920002558 Curdlan Polymers 0.000 claims description 3
- 108020004414 DNA Proteins 0.000 claims description 3
- 102000009123 Fibrin Human genes 0.000 claims description 3
- 108010073385 Fibrin Proteins 0.000 claims description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 3
- 229920002148 Gellan gum Polymers 0.000 claims description 3
- 229920001503 Glucan Polymers 0.000 claims description 3
- 229920002907 Guar gum Polymers 0.000 claims description 3
- 229920000084 Gum arabic Polymers 0.000 claims description 3
- 229920000161 Locust bean gum Polymers 0.000 claims description 3
- 108020004459 Small interfering RNA Proteins 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- UGXQOOQUZRUVSS-ZZXKWVIFSA-N [5-[3,5-dihydroxy-2-(1,3,4-trihydroxy-5-oxopentan-2-yl)oxyoxan-4-yl]oxy-3,4-dihydroxyoxolan-2-yl]methyl (e)-3-(4-hydroxyphenyl)prop-2-enoate Chemical compound OC1C(OC(CO)C(O)C(O)C=O)OCC(O)C1OC1C(O)C(O)C(COC(=O)\C=C\C=2C=CC(O)=CC=2)O1 UGXQOOQUZRUVSS-ZZXKWVIFSA-N 0.000 claims description 3
- 235000010489 acacia gum Nutrition 0.000 claims description 3
- 239000000205 acacia gum Substances 0.000 claims description 3
- 150000001450 anions Chemical class 0.000 claims description 3
- 229920000617 arabinoxylan Polymers 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 235000019316 curdlan Nutrition 0.000 claims description 3
- 229940078035 curdlan Drugs 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- 229950003499 fibrin Drugs 0.000 claims description 3
- 235000010492 gellan gum Nutrition 0.000 claims description 3
- 239000000216 gellan gum Substances 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 235000010417 guar gum Nutrition 0.000 claims description 3
- 239000000665 guar gum Substances 0.000 claims description 3
- 229960002154 guar gum Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 235000010420 locust bean gum Nutrition 0.000 claims description 3
- 239000000711 locust bean gum Substances 0.000 claims description 3
- 229940126586 small molecule drug Drugs 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 229940032147 starch Drugs 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 150000003973 alkyl amines Chemical class 0.000 claims description 2
- 125000005210 alkyl ammonium group Chemical group 0.000 claims description 2
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 claims description 2
- 125000005907 alkyl ester group Chemical group 0.000 claims description 2
- 150000008051 alkyl sulfates Chemical class 0.000 claims description 2
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 claims description 2
- 150000008052 alkyl sulfonates Chemical class 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 150000007942 carboxylates Chemical class 0.000 claims description 2
- 150000001768 cations Chemical class 0.000 claims description 2
- 229920000570 polyether Polymers 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 150000005846 sugar alcohols Polymers 0.000 claims description 2
- 150000003871 sulfonates Chemical class 0.000 claims description 2
- 150000003573 thiols Chemical class 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 239000003921 oil Substances 0.000 description 16
- 239000000499 gel Substances 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- 239000012071 phase Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 10
- 210000000130 stem cell Anatomy 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 239000000654 additive Substances 0.000 description 8
- 238000001000 micrograph Methods 0.000 description 8
- 235000010958 polyglycerol polyricinoleate Nutrition 0.000 description 8
- 239000003996 polyglycerol polyricinoleate Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 5
- ZNOZWUKQPJXOIG-XSBHQQIPSA-L [(2r,3s,4r,5r,6s)-6-[[(1r,3s,4r,5r,8s)-3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-4-[[(1r,3r,4r,5r,8s)-8-[(2s,3r,4r,5r,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-sulfonatooxyoxan-2-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-5-hydroxy-2-( Chemical compound O[C@@H]1[C@@H](O)[C@@H](OS([O-])(=O)=O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H]2OC[C@H]1O[C@H](O[C@H]1[C@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@@H]4OC[C@H]3O[C@H](O)[C@@H]4O)[C@@H]1O)OS([O-])(=O)=O)[C@@H]2O ZNOZWUKQPJXOIG-XSBHQQIPSA-L 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000011149 active material Substances 0.000 description 3
- 229940126523 co-drug Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000012459 cleaning agent Substances 0.000 description 2
- 239000008139 complexing agent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000002826 coolant Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000005416 organic matter Substances 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000006177 biological buffer Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000001109 blastomere Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229920003087 methylethyl cellulose Polymers 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 210000001074 muscle attachment cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 235000021085 polyunsaturated fats Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000010944 pre-mature reactiony Methods 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000003014 totipotent stem cell Anatomy 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K23/00—Use of substances as emulsifying, wetting, dispersing, or foam-producing agents
- C09K23/34—Higher-molecular-weight carboxylic acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K23/00—Use of substances as emulsifying, wetting, dispersing, or foam-producing agents
Definitions
- the invention relates to a composition comprising an emulsion, more specifically a double emulsion, for use in the delivery of active ingredients, a process for making said composition, a method of delivering active ingredients using the composition and methods of treatment using the composition.
- Emulsifiers In order to achieve stable dispersions of one liquid in another, emulsions in the traditional sense require the addition of an interface-active substance (emulsifier).
- Emulsifiers have an amphiphilic molecular structure, consisting of a polar (hydrophilic) and a nonpolar (lipophilic) molecular moiety, which are spatially separate from one another.
- finely disperse droplets of one phase, surrounded by an emulsifier shell water droplets in water-in-oil [W/O] emulsions or lipid vesicles in oil-in-water [O/W] emulsions
- Emulsifiers lower the interfacial tension between the phases by positioning themselves at the interface between the two liquids. At the phase boundary, they form oil/water interfacial films, which prevent irreversible coalescence of the droplets. Emulsions are frequently stabilized using emulsifier mixtures.
- Oil based formulations are obtained by dissolving, emulsifying and/or suspending active materials in an oil phase.
- Such products are employed across a range of technology and business sectors that includes pharmaceutical agents, food additives, cleaning agents, complexing agents, personal care substances, lubricants, adhesives, heating/cooling agents, colourants, indicators and crop protection chemicals.
- Water-in-oil emulsions oil continuous emulsions
- Water-based formulations water as the continuous phase
- Water-based formulations water as the continuous phase
- Hydrocolloids are compounds which swell when reacted with water to form gel like materials.
- Well known examples of hydrocolloids include gellatin and pectin which are readily obtainable from natural sources. These materials, when mixed with water and heated, form gel like structures and can be tailored in their properties by varying the ratio of water to hydrocolloid and treatment conditions. Such gel-like structures are very useful for supporting and/or entrapping active ingredients in order to preserve or protect said active ingredients from damage or to provide delayed or slow release in vivo.
- cross-linked gels containing cells has been known for a number of years. For example, using cells trapped within a gel matrix.
- US2005/0003010A describes a cross-linked alginate obtained by cross-linking sodium alginate solution by the addition of calcium ions to form a gel.
- Such gels are used to induce cell proliferation, by, for example, injecting the solution into damaged tissue.
- the cross-linking is broken on shearing, for example by passing through a needle to a site to be treated.
- US2007/0116680 describes embedding stem cells in a three dimensional hydrogel. Stem cells are suspended in a matrix solution, the matrix is gelled and the cells are contained within microbeads formed from the matrix. Hydrogel encapsulated stem cells are also disclosed in US2012/0027860A. Adipose-derived mesenchymal stem cells are mixed with a gel forming solution prior to causing the solution to gel.
- Another method for introducing active ingredients into hydrocolloids is to heat the hydrocolloid above its melting point and then gradually allow this to cool in solution, encapsulating active ingredients as it does so.
- WO2011/077073 and WO2014/ 140549 each describe a processes wherein solutions containing hydrocolloids ("monoglyceride and triglyceride” and “alginate") are heated to temperatures of approximately 70°C and 90°C respectively in order to create the necessary hydrocolloid gels.
- US 5,698,188 also described how carrageenan gels can be made by heat treating carrageenan in an aqueous solution at 90°C.
- hydrocolloid particles containing one or more active ingredients without requiring high temperatures.
- the invention is intended to overcome or at least ameliorate this problem.
- a process for making a double emulsion comprising the steps of: a) providing a first aqueous solution comprising: a hydrocolloid and one or more active ingredients; b) shearing the solution of step a); c) adding the composition from step b) to a hydrophobic solution comprising a first emulsifier; d) shearing the solution of step c) to form a primary emulsion; e) adding the emulsion of step d) to a second aqueous solution comprising a second emulsifier; and f) shearing the composition of e) to form a double emulsion; wherein the first aqueous solution is charged.
- the double emulsion that is produce by the process of the invention is typically for use in delivering active ingredients to a target site, typically this is in the body.
- primary emulsion as used herein is intended to refer to a mixture of hydrocolloid particles which are substantially uniformly dispersed throughout a hydrophobic phase, the particles being prevented from agglomerating by virtue of an emulsifying agent associating with the hydrocolloid particles at the interface between the particles and the hydrophobic phase. This may be described as a, “gel-in-oil” emulsion.
- double emulsion as used herein is intended to refer to the product of adding the primary emulsion to a hydrophilic phase with a further emulsifier. This results in particles having a hydrocolloid core and an outer "jacket” of hydrophobic solution. The particles are substantially uniformly dispersed throughout an aqueous phase (the second aqueous phase) and are prevented from prevented from rupturing due to emulsifiers at the core-jacket interface and the jacket-solution interface. This may be described as a, "gel-in- oil-in-water” emulsion.
- the temperature of the process is typically less than the melting point of the hydrocolloid or hydrocolloids used in the process. Typically, the temperature is also lower than that required to denature or degrade the active ingredients for incorporation into the hydrocolloid particles. As such, although the absolute maximum temperature of the process is determine by the materials used in a given process, it is typically the case that the temperature is less than 80°C, more typically less than 70°C, more typically less than 60°C, more typically less than 50°C, more typically less than 40°C and most typically about 30°C. As the process occurs in aqueous media, it is also the temperature is typically controlled to be high enough to prevent freezing of the solvent or active ingredients (especially wherein the active ingredients are cells). Typically, the temperature is set to provide a balance between preventing degradation of active ingredients and providing adequate reaction kinetics.
- the rate of shearing is determined by the robustness of the materials to be incorporated into the hydrocolloid particles. There is no particular restriction on the shear rate used provided that the components of the composition, particularly the active ingredients, will tolerate such shear rates without degrading. For example, where the active ingredients are cells, the shearing applied to the solution at each of the stages is typically low (around 500 s -1 ) in order to prevent damage to the cells. However, where the active ingredients are small molecules, not so easily damaged by shear forces, higher shear rates can be used.
- the shear rate at each of the stages are each independently less than 2000 s -1 , more typically less than 1800 s -1 , more typically still, less than 1500 s -1 , even more typically less than 1000 s -1 .
- the shear rate will be less than 800 s -1 and more typically equal to or less than 500 s -1 .
- the shear rate is greater than 100 s -1 , typically greater than 200 s -1 and more typically greater than 400 s -1 .
- the duration of the shearing steps is not particularly limited and varies depending on the temperature, choice of hydrocolloid and aqueous solutions used. Often, the shearing is conducted until no further change in the solution is observed. Typically this is less than one hour, more typically less than 30 minutes and even more typically less than 10 minutes.
- a rheometer may be used to impart the shear force. This could be a dynamic shear rheometer, pipe or capillary rheometer, rotational cylinder rheometer or cone and plater rheometer, linear rheometer or combination thereof.
- hydrocoUoid as used herein is intended to take its typical meaning. Namely, a material which is hydrophilic and which, in the presence of water, swells to form particles. Typically, the hydrocoUoid forms gels and most typically the hydrocoUoid may be selected from one or more polymers, which may in some embodiments be cross -linked or cross-linkable.
- hydrocoUoid may be a naturally occurring hydrocoUoid such as polysaccharides or may be synthetic hydrocoUoid such as, for example, polyacrylates, and polyethylene glycol.
- the hydrocoUoid is a naturally occurring hydrocoUoid it is typically selected from: agar, agarose, arabinoxylan, carrageenan, gelatin, gellan gum, glucan, curdlan, pectin, xanthan gum, gum arabic, guar gum, locust bean gum, cellulose and derivatives thereof, alginate, fibrin and starch or combinations thereof.
- Suitable hydrocolloids include chitosan, dextran, collagen and hyaluronic acid.
- Typical examples of cellulose derivatives are those compounds wherein one or more of the hydroxyl groups have been functioned. Typically, these groups are reacted to form alloy groups, alkoxycarboxylic acid groups, alkyoxyesters, alkoxyethers, or combinations thereof.
- Typical cellulose derivatives include, carboxymethyl cellulose, methyl cellulose and ethyl cellulose.
- the hydrocoUoid is selected from carrageenan, gelatin, agar, alginate, cellulose, cellulose derivatives and combinations thereof. Carrageenan is most typically used.
- the melting point of the hydrocolloids used in the present invention is typically greater than 30°C, more typically greater than 40°C, even more typically greater than 50°C, more typically still greater than 60°C, even more typically still greater than 70°C, and most typically greater than 80°C.
- the size of the hydrocolloid particles are typically in the range ⁇ to ⁇ , more typically ⁇ to 500 ⁇ , more typically still ⁇ to ⁇ , and even more typically still
- active ingredients used herein is intended to refer the compound or compounds that are incorporated into the hydrocolloid particles at the centre of the particles of the emulsion produced by the method of the first aspect of the invention.
- the composition obtainable by the process of the first aspect of the invention can be used in a wide range of different applications, some of which are described below in more detail.
- the active ingredients are therapeutic agents.
- the therapeutic agents may be selected from the group consisting of, proteins, antibodies, DNA, RNA, siRNA, hormones, nutrients, growth factors, inflammatory compounds, stimulating factors, cells, small molecule drugs, or combinations thereof.
- Other compounds useful in maintaining cells with the hydrocolloid may be added and/or compounds to help appropriate differentiation of cells or direct the active ingredients to appropriate cell targets.
- the active ingredients are cells.
- the cells may be prokaryotic or eukaryotic.
- the cells are plant or animal cells, for example, bird, inspect, reptile, more typically mammal cells.
- Stem cells may be used.
- Stem cells are typically human or non-human, pluripotent or totipotent, typically not human totipotent stem cells.
- the stem cells may be obtained from cell banks or, for example, embryonic, non-embryonic (typically non-embryonic human stem cells), cord blood stem cells or adult mesenchymal stem cells. They may be obtained from single blastomere biopsy, a non-destructive method of producing embryonic stem cells, or from adult cells such as iPS (induced pluripotent stem) cells. Other cells such as differentiated cell lines, or cells isolated from the blood or tissue may be used. The cells may be a patient's own cells. They may be autologous cells.
- They may be osteoblasts/MC 3T3 osteoblast like cells, chondrocytes, keratinocytes, fibroblasts, dermal fibroblasts, tenocytes, neurons, osteocytes, osteoclasts, adipocytes or any other cell type with therapeutic activity.
- additives may be used in tandem with the one or more therapeutic agents.
- flavourings i.e. drugs which work synergistically with another therapeutic agent
- vitamins pre-biotics
- pro-biotics pro-biotics
- additives include, for example, flavourings in order to mask unpleasant taste, co- drugs to counteract side-effects and/or other compounds to promote other synergistic effects.
- the first and second emulsifiers are typically selected from: anionic surfactants, cationic surfactants, non-ionic surfactants, or combinations thereof.
- anionic surfactants include: carboxylates (such as fatty acids), sulfonates (such as alkyl sulfonates and aryl sulfonates), sulfates (such as alkyl sulfates, alkylether sulfates, sulfated alkanolamides and/or phosphonated sulfates) and combinations thereof.
- typical cationic surfactants include: alkyl amines, and alkyl ammonium salts, aromatic or saturated heterocylic compounds (such as alkyl pyridines and alkyl imidazoles), or combinations thereof.
- non-ionic surfactants may be used.
- non-ionic surfactant There is no particular limitation on the choice of non-ionic surfactant.
- Typical examples of non-ionic surfactants are selected from: ethoxylated linear alcohols, ethoxylated alkyl phenols, alkyl esters (such as fatty acid esters), polyalcohols, poly ethers copolymers, thiols and combinations thereof.
- the one or more first and second emulsifiers used in the process of the invention are polymeric.
- the inventors have found that emulsifiers with a high molecular weight, comparable with polyglycerol polyricinoleate (PGPR) tend to provide improved stabilisation of double emulsions.
- Typical emulsifiers include, but are not limited to, polyglycerols, typically functionalised with one or more alkyl chains such as fatty acids. In particular, wherein the alkyl chains are greater than 10 carbons in length, typically greater than 30, or more typically greater than 50, or even more typically greater than 100 carbons in length.
- High molecular weight emulsifiers with large structures have been found to offer improved stability to double emulsion particles, especially where such emulsifiers are used as the first emulsifier.
- the first aqueous solution typically comprises cations, anions, zwitterions or a combination thereof.
- the inventors have found that having a charged aqueous solution improves the dissolution and hydrocoUoid particle forming process of step a) however there is no particular restriction on the charged particles that provide charge.
- the term "charged aqueous solution” is intended to refer to a solution comprising some water and at least some charged particles or species, typically ions. It is often the case that the first aqueous solution is anionic, however the first aqueous solution may also be cationic.
- the first aqueous solution will often be a buffer solution, preferably a biological buffer suitable for medical applications.
- step b It is typically the case that, after the first aqueous solution has been made (typically by adding the hydrocoUoid and active ingredients to a charged aqueous solvent) it is then immediately sheared according to step b).
- the inventors have found that if the first aqueous solution of step a) is left to stand for a prolonged period of time, the hydrocoUoid solution may aggregate and make micronisation of the hydrocoUoid difficult. Accordingly, the delay between making the first aqueous solution and shearing the solution in step b) is typically less than 5 minutes, more typically less than 1 minute, and more typically still less than 30 seconds.
- the concentration of hydrocoUoid used in the first aqueous solution there is no particular restriction on the concentration of hydrocoUoid used in the first aqueous solution.
- the amount of hydrocoUoid is less than 25% by weight of the first aqueous solution, more typically less than 20%, more typically still less than 10%. It is often the case that the amount of hydrocoUoid used is in the range of 1% to 10% by weight of the first aqueous solution, more typically, in the range of 5% to 10% and even more typically about 8% hydrocoUoid by weight of the first aqueous solution.
- hydrophobic solution used in the process of the invention is not particularly limited, however it is typically the case that the hydrophobic solution is biocompatible and is often a lipid.
- Typical hydrophobic solutions include any non-polar solution typical examples of which include: naturally occurring and synthetic oils, waxes, fats and combinations thereof. These may be derived from animals or plants, such as sunflower oil, or mineral oils and/or fractions thereof.
- the ratio of the first aqueous solution to the hydrophobic solution is typically in the range of 50: 1 to 1:50 respectively, more typically 20: 1 to 1:20, more typically still 10: 1 to 1: 10 and even more typically still in the range 5: 1 to 1:5. It is often the case that the ratio will be in the range 2: 1 to 1:2 and furthermore, the ratio may be about 1: 1.
- the second aqueous solution is less limited on its composition as there is no need for this solution to be charged, although the solution may be charged and/or as described for the first aqueous solution.
- the ratio of the primary emulsion to the second aqueous solution is typically in the range of 50: 1 to 1:50 respectively, more typically 20: 1 to 1:20, more typically still 10: 1 to 1: 10 and even more typically still in the range 5: 1 to 1:5. It is often the case that the ratio will be in the range 2: 1 to 1:2 and furthermore, the ratio may be about 1: 1.
- the process of the first aspect of the invention may further comprising a sterilisation step which may be via irradiation or chemical means.
- Irradiation may utilise, for example, ultraviolet, x-ray or gamma ray radiation to sterilise the medium, for example, to remove unwanted bacterial contamination.
- the choice of sterilisation depends on the particular active ingredients being incorporated into the hydrocolloid particles.
- an aqueous composition comprising an aqueous solvent and one or more particles, the particles comprising: a hydrocolloid core comprising one or more active ingredients; an hydrophobic layer adjacent the hydrocolloid core; a first emulsifier positioned between the hydrocolloid core and the hydrophobic layer; and a second emulsifier positioned between the hydrophobic layer and the aqueous solvent; wherein the one or more active ingredients are thermally sensitive.
- thermosensitive is intended to encompass those compounds, substances and/or organic matter that cannot be incorporated into hydrocolloids using traditional methods that involve melting of the hydrocolloids. Therefore, it is usually the case that the active ingredient used in the composition of the invention are only thermally stable below the melting point of the hydrocolloid. There is no particular restriction on the temperature as this depends largely on the particular choice of hydrocolloid. However, the term “thermally sensitive” is typically intended to cover compounds, substances and/or organic matter which degrades (or at least begins to degrade) above 80°C, more typically above 70°C, even more typically above 60°C, more typically still above 50°C, even more typically still above 40°C and most typically above 30°C.
- the composition is typically a delivery medium.
- delivery medium is intended to mean, a system for delivery active ingredients to a particular target site.
- the emulsion described herein can be used to entrap active ingredients that would otherwise breakdown in certain environments. This is particularly true when used in vivo and the composition may be used to transport active ingredients to regions where they would not otherwise reach, for instance due to incompatible solubility, poor pH stability or premature reaction with other materials in vivo.
- the delivery medium is a cell delivery medium.
- the active ingredients are substantially confined to the hydrocolloid core.
- the active ingredient may be dispersed through the hydrocolloid core and/or distributed across the surface of the core.
- the active ingredients are distributed throughout the hydrocolloid core.
- the composition is a double emulsion.
- the aqueous composition may be obtainable by way of the process of the first aspect of the invention.
- the process of the first aspect of the invention has made possible the fabrication of new compositions and emulsions wherein heat sensitive materials can be introduced into hydrocolloid particles.
- the composition is used as an active ingredient delivery system.
- the composition is used as a delivery system for a therapeutic agent such as those described above. More typically, the composition is a cell delivery system.
- the present invention is particular suitable to encapsulating therapeutic agents, especially cells.
- the composition may comprise two or more therapeutics. This is particularly desirable wherein the disease to be treated is very resistant to a single therapeutic and/or wherein one therapeutic induces side-effects which can be counteracted by the second therapeutic.
- Additives may also be used together with the one or more active ingredients.
- Typical additives include: flavourings (especially useful for paediatric applications, in order to mask the taste of unpleasant tasting drugs), co-drugs (compounds that work synergistically with other active ingredients, for instance to inhibit side-effects or improve efficacy), vitamins, minerals or nutrients (for instance to supply a patient with nutrition or to keep any cells to be delivered healthy for a desired duration in transits through the body or for storage purposes), colourings or combinations thereof.
- flavourings especially useful for paediatric applications, in order to mask the taste of unpleasant tasting drugs
- co-drugs compounds that work synergistically with other active ingredients, for instance to inhibit side-effects or improve efficacy
- vitamins, minerals or nutrients for instance to supply a patient with nutrition or to keep any cells to be delivered healthy for a desired duration in transits through the body or for storage purposes
- colourings or combinations thereof There is no particular restriction on the choice of additive, providing that it does not negatively interfere with the operation of the
- the composition may be used as an additive in food products.
- the emulsion of the invention allows a range of nutrients (such as amino acids, proteins, polyunsaturated fats and oil), nutraceuticals (such as vitamins and/or minerals) and additives (e.g. flavourings, drugs, pH stabilisers, etc.) to be introduced into many common food products that would not otherwise be soluble or stable therein. This reduces the amount of fats needed in conventional products to "carry" such materials.
- Typical examples of food products include: mayonnaise, sauces, water or lipid continuous spreads, dips, confectionary, and drinks.
- compositions according to the second aspect of the invention for use in the treatment of disease.
- Typical diseases include, but are not limited to: cancer, bacterial or viral infection and nutrient deficiency.
- the composition may also be used treat diseased or damaged tissue.
- a fourth aspect of the invention a method of treating a disease comprising the steps of administering the composition, containing one or more therapeutic agents, to a patient.
- composition of the invention can be used to deliver therapeutic agents to target sites within the body and may be used to repair or augment the repair of damaged or diseased tissue. This is particularly the case when the active ingredient comprises cells, such as stem cells.
- composition of according to the second aspect of the invention in the delivery of active ingredients.
- this is intended to cover specific regions within the body but could also include the delivery of active ingredients to cells, or materials outside the body for instance in industrial processes or research applications.
- FIGURE 1 shows Kappa carrageenan in DMEM (Dulbecco's Modified Eagle's Medium) at a range of concentrations (2% (a), 4% (b), 5% (c), 6% (d), 7% (e) and 8% (f)). Samples were formed at 30°C, and sheared at 500 s -1 for 60 minutes, using a rheometer.
- DMEM Denbecco's Modified Eagle's Medium
- FIGURE 2 shows inverted vials of 6% (a), 7% (b) and 8% (c) kappa carrageenan in DMEM. Photographs were taken after vials had been inverted for 3 hours.
- FIGURE 3 shows differential scanning calorimetry (DSC) heating (a) and cooling (b) profiles for different concentrations of KC (0% ( ⁇ ), 2% ( ⁇ ), 4% ( ⁇ ), 6% ( T ), 7% (0), and 8% ( ⁇ )) dispersed in DMEM buffer.
- DSC differential scanning calorimetry
- FIGURE 4 shows Kappa carrageenan in HEPES (4-(2-hydroxyethyl)-l- piperazineethanesulfonic acid) at a range of concentrations (2% (a), 4% (b), and 6% (c)). Samples were formed at 30°C, and sheared at 500 s-1 for 60 minutes, using a rheometer.
- FIGURE 5 shows differential scanning calorimetry (DSC) heating (a) and cooling (b) profiles for different concentrations of KC (0% ( ⁇ ), 2% ( ⁇ ), 4% ( ⁇ ), 5% ( T ) and 6% (0)) dispersed in HEPES buffer.
- FIGURE 6 shows oil continuous emulsions with DMEM as the aqueous phase (a) and with warm (30°C) water hydrated kappa Carrageenan at 2% (b), 4% (c), 5% (d), 6% (e), 7% (f) and 8% (g) kappa carrageenan in DMEM, emulsified with 1% PGPR.
- FIGURE 7 shows micrographs of duplex emulsions with the inclusion of 6% (a, d), 7% (b, e) and 8% (c, f) KC dispersed in DMEM buffer. Inner droplets were stabilised with PGPR, and outer droplets stabilised with Tween 20 (a, b, c) and Tween 80 (d, e, f). Micrographs were taken immediately after forming the duplex emulsion.
- FIGURE 8 shows micrographs of duplex emulsions with the inclusion of 5% (a, c) and 6% (b, d) KC dispersed in HEPES buffer. Inner droplets were stabilised with PGPR, and outer droplets stabilised with Tween 20 (a, b) and Tween 80 (c, d). Micrographs were taken immediately after forming the duplex emulsion.
- FIGURE 9 shows micrographs of duplex emulsions with the inclusion of 6% (a, d), 7% (b, e) and 8% (c, f) KC dispersed in DMEM buffer. Inner droplets were stabilised with Span 80, and outer droplets stabilised with Tween 20 (a, b, c) and Tween 80 (d, e, f). Micrographs were taken immediately after forming the duplex emulsion.
- FIGURE 10 shows micrographs of duplex emulsions with the inclusion of 5% (a, c) and 6% (b, d) KC dispersed in HEPES buffer. Inner droplets were stabilised with Span 80, and outer droplets stabilised with Tween 20 (a, b) and Tween 80 (c, d). Micrographs were taken immediately after forming the duplex emulsion.
- Example 1 Method of Making Hydrocolloid Double Emulsion
- Hydrocolloid particulate systems are formed through shearing the dry hydrocolloid powder (up to 10%) with an anion/buffer solution, at 30°C (using a Malvern Instruments rheometer - cup and vane geometry).
- the shear used is a low shear (500 s -1 ).
- the particulate systems are self-supporting, but flow under low strains. This behaviour is similar to a fluid gel system.
- the particulate system is mixed with oil (paraffin oil) and an emulsifier (PGPR, Span 80) to form oil continuous primary emulsions, whereby the hydrocolloid particulate structure is contained within the droplet.
- the particulate to oil phase was in a 1 : 1 ratio.
- the formation of the primary emulsions was carried out using low shear and a controlled low temperature (using a Malvern Instruments rheometer - cup and vane geometry). However, the formation of primary emulsions can be carried out using high shear rates.
- Stable primary emulsion formulations were then emulsified with a polysorbate (Tween 20, Tween 80) to form water continuous double (or duplex) emulsions (gel/oil/water).
- the formation of the duplex emulsions was carried out using a Malvern Instruments rheometer, at low shear rates.
- the formation of duplex emulsions is carried out at lower shear rates than for primary emulsions to avoid droplet breakup.
- the formation of these emulsions is not typically as low as 500 s -1 (the shear rate used here).
- the primary emulsions were stable irrespective of emulsifier, double emulsions were less stable when Span 80 was used to stabilise the first interface between the hydrocolloid and oil layer.
- Figures 9 and 10 show that one or less primary emulsion droplets were seen inside secondary droplets.
- the use of PGPR (a larger emulsifier that can aggregate and bind more strongly to the interface than Span 80) formed duplex emulsions whereby multiple internal droplets are present within every secondary droplet. Double emulsions using PGPR were found to be stable for multiple weeks.
- Table 3 Droplet sizes for the stable emulsions, determined using a mastersizer. Values quoted are the peak maximum, or modal number.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Materials Engineering (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention concerne un procédé de préparation d'une émulsion, comprenant les étapes consistant à : a) fournir une première solution aqueuse comprenant : un hydrocolloïde et un ou plusieurs ingrédients actifs ; b) cisailler la solution de l'étape a) ; c) ajouter la composition obtenue à l'étape b) à une solution hydrophobe comprenant un premier émulsifiant ; d) cisailler la solution de l'étape c) pour former une émulsion primaire ; e) ajouter l'émulsion primaire de l'étape d) à une seconde solution hydrophile comprenant un second émulsifiant ; et f) cisailler la composition de l'étape e) pour former une émulsion double ; la première solution aqueuse étant chargée. L'invention concerne également une composition comprenant un solvant aqueux et une ou plusieurs particules, les particules comprenant : un noyau hydrocolloïdal comprenant un ou plusieurs ingrédients actifs ; une couche hydrophobe adjacente au noyau hydrocolloïdal ; un premier émulsifiant placé entre le noyau hydrocolloïdal et la couche hydrophobe ; et un second émulsifiant placé entre la couche hydrophobe et le solvant aqueux ; le ou les ingrédients actifs étant thermosensibles.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1608595.3 | 2016-05-16 | ||
GB1608656.3 | 2016-05-17 | ||
GBGB1608656.3A GB201608656D0 (en) | 2016-05-17 | 2016-05-17 | Emulsion |
GBGB1608595.3A GB201608595D0 (en) | 2016-05-19 | 2016-05-19 | Emulsion |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017199008A1 true WO2017199008A1 (fr) | 2017-11-23 |
Family
ID=58745266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2017/051343 WO2017199008A1 (fr) | 2016-05-16 | 2017-05-15 | Émulsion |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2017199008A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022063883A1 (fr) | 2020-09-23 | 2022-03-31 | Secoya Technologies | Procédé d'encapsulation d'une solution aqueuse comprenant un composé d'intérêt dans une matrice |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0278103A2 (fr) * | 1987-01-12 | 1988-08-17 | American Cyanamid Company | Préparations d'hormones de croissance à libération prolongée administrables par voie parentérale et leurs utilisations |
-
2017
- 2017-05-15 WO PCT/GB2017/051343 patent/WO2017199008A1/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0278103A2 (fr) * | 1987-01-12 | 1988-08-17 | American Cyanamid Company | Préparations d'hormones de croissance à libération prolongée administrables par voie parentérale et leurs utilisations |
Non-Patent Citations (2)
Title |
---|
CARLOS J. MARTINEZ ET AL: "A Microfluidic Approach to Encapsulate Living Cells in Uniform Alginate Hydrogel Microparticles", MACROMOLECULAR BIOSCIENCE, vol. 12, no. 7, 7 February 2012 (2012-02-07), DE, pages 946 - 951, XP055389180, ISSN: 1616-5187, DOI: 10.1002/mabi.201100351 * |
HON FAI CHAN ET AL: "Efficient One-Step Production of Microencapsulated Hepatocyte Spheroids with Enhanced Functions", SMALL, vol. 12, no. 20, 1 April 2016 (2016-04-01), DE, pages 2720 - 2730, XP055389172, ISSN: 1613-6810, DOI: 10.1002/smll.201502932 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022063883A1 (fr) | 2020-09-23 | 2022-03-31 | Secoya Technologies | Procédé d'encapsulation d'une solution aqueuse comprenant un composé d'intérêt dans une matrice |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lu et al. | Sustained release of PI3K inhibitor from PHA nanoparticles and in vitro growth inhibition of cancer cell lines | |
Reis et al. | Review and current status of emulsion/dispersion technology using an internal gelation process for the design of alginate particles | |
Ng et al. | Novel microencapsulation of potential drugs with low molecular weight and high hydrophilicity: hydrogen peroxide as a candidate compound | |
CN101415395B (zh) | 酪蛋白纳米粒子 | |
Lei et al. | Fabrication of nanoemulsion-filled alginate hydrogel to control the digestion behavior of hydrophobic nobiletin | |
Meng et al. | Chitosan-based Pickering emulsion: A comprehensive review on their stabilizers, bioavailability, applications and regulations | |
CN1638735A (zh) | 立方液晶组合物及其制备方法 | |
KR20080018862A (ko) | 함유 고형물 및 그의 제조방법 | |
Aggarwal et al. | Pharmaceutical polymer gels in drug delivery | |
JP2013530168A (ja) | 親水性活性物質のためのコロイド状ナノスケールキャリア及びその製造方法 | |
Lima et al. | Microbubbles as biocompatible porogens for hydrogel scaffolds | |
Wang et al. | Parenteral thermo-sensitive organogel for schizophrenia therapy, in vitro and in vivo evaluation | |
Wang et al. | Electrosprayed soft capsules of millimeter size for specifically delivering fish oil/nutrients to the stomach and intestines | |
JP5531230B2 (ja) | 油性外用製剤及びその製造方法 | |
Weng et al. | Improved enzyme thermal stability, loading and bioavailability using alginate encapsulation | |
CN104955460B (zh) | 乳化组合物 | |
Khan et al. | Recent advances in microbeads-based drug delivery system for achieving controlled drug release | |
WO2017199008A1 (fr) | Émulsion | |
Hijo et al. | High-intensity ultrasound assisted-emulsification using ionic liquids as novel naturally-derived emulsifiers for food industry applications | |
CN103520102A (zh) | 一种维生素d纳米乳及其制备方法 | |
CN103819696A (zh) | 一种表面皱褶明胶/透明质酸复合微球的制备方法 | |
CN103211753A (zh) | 一种凝胶剂基质 | |
JP6192047B2 (ja) | レシチンオルガノゲル形成剤 | |
JP2020503244A (ja) | 自己乳化型脂質組成物 | |
WO2010082487A1 (fr) | Gélifiant d'huile comprenant des micelles inverses en forme de ver et composition de type gel épaissie |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17724882 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17724882 Country of ref document: EP Kind code of ref document: A1 |